Diabetic Macular Edema (DME) Recruiting Phase 3 Trials for Brolucizumab (DB14864)

Also known as: Diabetic Macular Edema / Macular Edema, Diabetic / Diabetic Macular Oedema / Diabetic retinal oedema / Diabetic retinal edema

IndicationStatusPhase
DBCOND0060562 (Diabetic Macular Edema (DME))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04058067To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular EdemaTreatment
NCT03481660A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaTreatment
NCT03481634Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaTreatment